Last reviewed 2026-04-19 · How we verify

Juanbi pill

Cui xuejun · Phase 2 active Small molecule

Juanbi pill is a Small molecule drug developed by Cui xuejun. It is currently in Phase 2 development. Also known as: Experimental: Juanbi group, Placebo Comparator: placebo group.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Juanbi pill
Also known as	Experimental: Juanbi group, Placebo Comparator: placebo group
Sponsor	Cui xuejun
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Juanbi Pill for Rheumatoid Arthritis (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Juanbi pill CI brief — competitive landscape report
Juanbi pill updates RSS · CI watch RSS
Cui xuejun portfolio CI

Frequently asked questions about Juanbi pill

What is Juanbi pill?

Juanbi pill is a Small molecule drug developed by Cui xuejun.

Who makes Juanbi pill?

Juanbi pill is developed by Cui xuejun (see full Cui xuejun pipeline at /company/cui-xuejun).

Is Juanbi pill also known as anything else?

Juanbi pill is also known as Experimental: Juanbi group, Placebo Comparator: placebo group.

What development phase is Juanbi pill in?

Juanbi pill is in Phase 2.

Manufacturer: Cui xuejun — full pipeline
Also known as: Experimental: Juanbi group, Placebo Comparator: placebo group

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing